December 11, 2015 | Nanomedical Diagnostics of San Diego has appointed a three-member scientific advisory board, who will help guide the company through beta testing and early commercialization of its first research-use and diagnostic products.
Nanomedical Diagnostics, or Nanomed, was founded in September by CEO Ross Bundy and CTO Brett Goldsmith, based on Goldsmith’s work at the University of Pennsylvania on using carbon nanotubes in field effect transistors to detect biomolecular reactions. The technology, which can be multiplexed on a handheld device, measures changes in an electrical charge conducted across a graphene structure, which occur when a biomarker binds with an antibody or capture probe. It can be used to identify proteins and nucleic acids in biological samples.
The first diagnostic for Nanomed’s platform will target antigens carried by the bacterium that causes Lyme disease.
The new scientific advisory board includes Timothy Broderick of Wright State Research Institute, University of California President Emeritus Robert Dynes, and Jayakumar Rajadas of Stanford School of Medicine.